ARMSTRONG, A. W. .; LEBWOHL, M. .; WARREN, R. B. .; SOFEN, H. .; MORITA, A. .; IMAFUKU, S. .; OHTSUKI, M. .; SPELMAN, L. .; PASSERON, T. .; PAPP, K. A. .; COLOMBO, M. J. .; VAILE, J. .; VRITZALI, E. .; HOYT, K. .; DAAMEN, C. .; BANERJEE, S. .; STROBER, B. .; THAÇI, D. .; BLAUVELT, A. . Deucravacitinib in Plaque Psoriasis: 4-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1, PSO-2, and LTE Trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 8, n. 4, p. s406, 2024. DOI: 10.25251/skin.8.supp.406. Disponível em: https://jofskin.org/index.php/skin/article/view/2854. Acesso em: 23 jul. 2024.